- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02347540
Heart Failure and Related Risk-factors After Preeclampsia (QoH)
Queen of Hearts Research Program. Identifying the Risk on Heart Failure After Preeclampsia.
This study is a cross-sectional case-control study where classical as well as more innovative risk factors for CVD will be explored.
In western countries, more women than men die of cardiovascular disease (CVD), making CVD in women an important public health issue. Misdiagnosis of CVD in women is frequently observed, posing the clinician for diagnostic and therapeutic dilemmas that can easily result in inadequate treatment and worse prognosis. Despite these challenges, CVD in women has been underexposed in scientific research.
Women have gender-specific risk factors like a history of preeclampsia (PE) that contribute to their risk for CVD. PE complicates 5-10% of pregnancies, recurs in ~25% and is associated with a 2-4 fold increased risk for CVD. Moreover, pre-symptomatic heart failure (HF) stage B occurs in 40% of women with a history of PE. HF stage B is thought to precede the development of the, mortality related, clinical HF stages C and D (structural heart disease in combination with symptomatic disease). Early detection and tailored intervention of women with stage B HF decreases progression to the clinical stages and might therefore improve clinical outcome and cardiovascular related mortality.
Phenotypic presentation of HF is currently split up between systolic HF also called HF with reduced ejection fraction (HFrEF) and diastolic HF or HF with preserved ejection fraction (HFpEF). Women more often have HFpEF in contrast to men. Different pathophysiology and disease progression in women compared to men seems to be an important underlying factor. The current clinical HF diagnostic tools (e.g. natriuretic hormones and high sensitivity troponins) fail to identify early changes that prelude adverse cardiac remodelling and HF, and do not discriminate between HFrEF and HFpEF. Moreover, there are sex-related differences in biomarker levels for detection of CVD. As a result, clinicians are forced to wait for the failing heart to become clinically evident before they can intervene. Therefore, there is an urgent need to assess novel biomarkers that could help select high risk women needing further follow up and intervention. Biomarkers may not only improve early diagnosis but may also unravel disease pathways of HFpEF. Especially when combined with measurements of subclinical, surrogate risk markers.
Objectives
- To determine the impact of PE on incidence of macro-and micro-vascular dysfunction reflected by surrogate measures for coronary artery disease (CAD) and HFpEF.
- To perform a genome wide association study (GWAS) and associate novel biomarker expression levels with endothelial function, cardiac diastolic function and IMT measurement.
- To identify risk factors and surrogate measures for CVD in a) former PE patients without HFpEF, b) former PE patients with HFpEF and c) healthy parous controls.
Study population Cases: women with a history of PE Controls: women with uncomplicated pregnancies in the history. Measurements will be performed in clusters at postpartum intervals of: ½-2, 5-10, 10-15 and 15-30 years. Number of inclusions will be: 425, 350, 282 and 233 for each follow-up group respectively.
Primary endpoints The prevalence of macro- and microvascular dysfunction in former PE patients. Novel biomarker detection in former PE patients associated with HF in general and HFpEF in particular.
Secondary endpoints
- Lifestyle (questionnaire)
- Cognitive ability (questionnaire)
- Depression score (questionnaire)
- Metabolic syndrome (MetS)
- Arterial endothelial function (Flow mediated dilation (FMD))
- Intima Media Thickness (IMT)
- Glycocalyx thickness (by means of the Glycocheck)
- Venous function (plethysmograph)
- Electrocardiogram (ECG)
- Ergometry
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Limburg
-
Maastricht, Limburg, Netherlands, 6202 AZ
- Maastricht University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Cases
- Women aged ≥ 18 years
- ½ till 30 years after the complicated pregnancy
- Experienced PE in any pregnancy. PE defined as hypertension (systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with the development of proteinuria (≥ 300 mg/ 24 hours).
- Women who had their last delivery at least 6 months ago.
Controls
- Women aged ≥ 18 years
- ½ till 30 years after the pregnancy that matches the sequence number of pregnancy of the specifically matched case.
- Experienced pregnancies that were not complicated by foetal or maternal placental syndrome (pregnancy induced hypertension, preeclampsia, HELLP-syndrome).
- Women who had their last pregnancy at least 6 months ago.
- Women with a negative family history for PE (mother and sisters did not experience PE).
Exclusion Criteria:
A potential subject who meets any of the following criteria will be excluded from participation in this study:
Cases
- Women with auto-immune diseases prior to the complicated pregnancy.
- Chronic hypertension prior to the complicated pregnancy.
- Renal disease prior to the complicated pregnancy.
- Pregnant women
- Women who do not want to be informed about the results of the tests, or women who do not want their general practitioner and specialist(s) to be informed about the test results.
Control group:
- Women with auto-immune diseases
- Chronic hypertension prior to the matched pregnancy.
- Women with IUGR in the matching pregnancy (p<10)
- Solutio placentae in the matching pregnancy
- Pregnant women
- Women who do not want to be informed about the results of the tests, or women who do not want their general practitioner and specialist(s) to be informed about the test results.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Women with a history of preeclampsia (cases)
Cases: women with a history of preeclampsia. Measurements will be performed in a postpartum interval from 0.5 years until 30 years after the first complicated pregnancy. This group will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure. |
Women with a history of uncomplicated pregnancy (controls)
Controls include women with a history of uncomplicated pregnancies.
The controlgroup will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The prevalence of Heart Failure (number with percentage)
Time Frame: At time of assessment
|
Heart Failure will be assessed with the transthoracic echocardiography based on the criteria of the American Heart Association.
The sub classification for Heart Failure with preserved ejection fraction (EF) will be made (EF >55%)
|
At time of assessment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Structural en Functional Cardiac Measurements
Time Frame: At time of assessment
|
The objective is to estimate structural and functional cardiac measurements with the TTE based on the ASA guidelines.
|
At time of assessment
|
Metabolic syndrome
Time Frame: At time of assessment
|
The objective is to assess the prevalence of constituents of the Metabolic syndrome based on the WHO criteria.
The prevalence will be reported in number with percentage.
|
At time of assessment
|
Arterial endothelial function (Flow mediated dilation (FMD))
Time Frame: At time of assessment
|
The objective is to estimate NO mediated endothelial function of the brachial artery with ultrasound by FMD and sublingual NTG administration.
FMD will be reported in relative increase in diameter (%).
|
At time of assessment
|
Common Carotid Intima media thickness
Time Frame: At time of assessment
|
The objective is to estimate IMT of the common carotid artery in cm using ultrasound.
|
At time of assessment
|
Glycocalyx thickness en microvascular tortuosity
Time Frame: At time of assessment
|
The objective is to estimate the glycocalyx dimensions using sublingual orthogonal polarization spectral (OPS) measurements.
Derivative of the glycocalyx (perfused boundary region) will be reported in um.
Tortuosity will be reported based on a score system.
|
At time of assessment
|
Cognitive, Lifestyle and Depression rates
Time Frame: At time of assessment
|
To evaluate subjective cognitive functioning and depression rates and lifestyle behavior in formerly preeclamptic women with heart failure compared to controls.
|
At time of assessment
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Marc EA Spaanderman, MD, PhD, Maastricht University Medical Center
- Study Chair: Gerard Pasterkamp, PhD, UMC Utrecht
- Study Chair: Hester HM den Ruijter, PhD, UMC Utrecht
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- METC 14-02-013
- 2013T084 (Other Grant/Funding Number: Nederlandse Hartstichting (Dutch Heart Foundation))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
Nanjing Medical UniversityRecruiting
-
Centre Hospitalier Universitaire de la RéunionRecruitingCardiovascular DiseaseFrance
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States